1) Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control 2014;21:231-7. 2) Dahan R et al. FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 2015;28:285-95. 3) Boyerinas B et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 2015;3:1148-57. 4) Kohrt HE et al. Combination strategies to enhance antitumor ADCC. Immunotherapy 2012;4:511-27. 5) Hamilton G, Rath B. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opin Biol Ther 2017;17:515-23.
(Logo: https://mma.prnewswire.com/media/765882/... )
Photo: https://mma.prnewswire.com/media/765882/...
CONTACT: Brenda Mulligan +1-978-821-5345, Investor relations+49-6151-72-3321
